skip to Main Content
NEWS
[Yakup] C&R Research Attracts Attention With Its ‘first Dividend’ Since Establishment

[Yakup] C&R Research attracts attention with its ‘first dividend’ since establishment

C&R Research announced that it has finalized a dividend of KRW 10 per share, totaling KRW 570 million, for 56,725,420…

Read more →
[FNNews] C&R Research Expands Globally Through CRO Business

[FNNews] C&R Research expands globally through CRO business

Growth Research assessed that C&R Research has the potential to expand its global influence through its Clinical Research Organization (CRO)…

Read more →
[Yakup] C&R Research Selected As A “2024 Best Work-Life Balance Company” In Korea

[Yakup] C&R Research selected as a “2024 Best Work-Life Balance Company” in Korea

C&R Research selected as a "2024 Best Work-Life Balance Company" in Korea!   "2024 Best Work-Life Balance Company" was newly…

Read more →
[Yakup] C&R Healthcare Global (Thailand), The Thai Subsidiary Of C&R Research, And KIMCo Signed An MOU To ‘Develop TBM In The ASEAN Region’

[Yakup] C&R Healthcare Global (Thailand), the Thai subsidiary of C&R Research, and KIMCo signed an MOU to ‘Develop TBM in the ASEAN region’

C&R Healthcare Global (Thailand) Co., Ltd., the Thai subsidiary of C&R Research, and KIMCo(Korea Innovative Medicines Consortium) signed an MOU…

Read more →
[MoneyToday] C&R Research, A Leading Clinical CRO In Korea, Embarks On Global Growth Journey

[MoneyToday] C&R Research, a Leading Clinical CRO in Korea, Embarks on Global Growth Journey

C&R Research continues to demonstrate its strength as a leading Contract Research Organization (CRO) by maintaining strong performance growth this…

Read more →
Back To Top